key: cord-0687300-8m5ef4oe
authors: Goh, Yun Shan; Chavatte, Jean-Marc; Jieling, Alicia Lim; Lee, Bernett; Hor, Pei Xiang; Amrun, Siti Naqiah; Yi-Pin Lee, Cheryl; Sin-Ling Chee, Rhonda; Wang, Bei; Lee, Chia Yin; Xian Ngoh, Eve Zhi; Wang, Cheng-I; Young, Barnaby Edward; Tambyah, Paul A.; Kalimuddin, Shirin; Pada, Surinder; Tan, Seow-Yen; Sun, Louisa Jin; I-Cheng Chen, Mark; Leo, Yee-Sin; Lye, David C.; Ng, Lisa F.P.; Pin Lin, Raymond Tzer; Renia, Laurent
title: Sensitive detection of total anti-Spike antibodies and isotype switching in asymptomatic and symptomatic COVID-19 patients
date: 2021-01-16
journal: Cell Rep Med
DOI: 10.1016/j.xcrm.2021.100193
sha: b7d92e7fb64aad2f37da3de803291cbd87c34a79
doc_id: 687300
cord_uid: 8m5ef4oe

Early detection of infections is crucial to limit the spread of coronavirus 2019 disease (COVID-19). Here, we develop a flow cytometry-based assay to detect SARS-CoV-2 Spike protein (S protein) antibodies in COVID-19 patients. The assay detects specific IgM, IgA and IgG in COVID-19 patients and also the acquisition of all IgG subclasses, with IgG1 being the most dominant. The antibody response is significantly higher at a later stage of the infection. Furthermore, asymptomatic COVID-19 patients also develop specific IgM, IgA and IgG, with IgG1 as the most dominant subclass. Although the antibody levels are lower in asymptomatic infections, the assay is highly sensitive and detect 97% of asymptomatic infections. These findings demonstrate that the assay can be used for serological analysis of symptomatic infections, and also asymptomatic infections, which may, otherwise, go undetected.

Early detection of infections is crucial to limit the spread of coronavirus 2019 disease 53 . Here, we develop a flow cytometry-based assay to detect SARS-CoV-2 Spike 54 protein (S protein) antibodies in COVID-19 patients. The assay detects specific IgM, IgA and 55 IgG in COVID-19 patients and also the acquisition of all IgG subclasses, with IgG1 being the 56 most dominant. The antibody response is significantly higher at a later stage of the infection. 57 Furthermore, asymptomatic COVID-19 patients also develop specific IgM, IgA and IgG, 58 with IgG1 as the most dominant subclass. Although the antibody levels are lower in 59 asymptomatic infections, the assay is highly sensitive and detect 97% of asymptomatic 60 infections. These findings demonstrate that the assay can be used for serological analysis of 61 symptomatic infections, and also asymptomatic infections, which may, otherwise, go 62 undetected. The coronavirus disease 2019 (COVID-19) is a major health issue affecting 216 76 countries, with 34 million confirmed human infection cases and more than 1 million fatalities 77 thus far 1 . By April 2020, a mere four months after the first case was reported, COVID-19 has 78 developed into a pandemic that has led to either a partial or total confinement of more than 79 half of the world's population. This unprecedented crisis has resulted in overwhelmed 80 healthcare systems and major socio-economic disruptions. illness onset (pio) [8] [9] [10] . 90 Serological assays that detect specific antibodies against SARS-CoV-2 10, 11 have 91 increasingly been utilised to complement PCR-based assays, especially in symptomatic 92 infections with low viral load. As of 17 August 2020, the U.S. Food and Drug Administration 93 (US-FDA) approved the use of 37 serological assays 12 , mainly targeting two immunogenic 94 proteins: (1) spike (S) protein, which is the most exposed viral protein, and (2) nucleocapsid 95 (N) protein, which is abundantly expressed during infection [13] [14] [15] . The S protein is responsible 96 for the binding and entry of the virus into the host cell via the cellular receptor, angiotensin-97 converting enzyme 2 (ACE2) 16 . Many S protein-based serological assays are ELISA assays, 98 J o u r n a l P r e -p r o o f 6 which are based on linear peptides, to detect specific antibodies to either the S1 subunit, S2 99 subunit or the receptor binding domain (RBD) 14, [17] [18] [19] , which may not capture the full 100 repertoire of antibodies such as antibodies binding to various domains and conformational 101 epitopes of the S protein.

In this report, we have developed a sensitive and time-efficient flow cytometry-based 103 assay that detects antibodies against the full-length SARS-CoV-2 S protein. Using lentiviral-104 transduced cells that express the full length S protein stably on the cell surface, we aimed to 105 examine a wider repertoire of antibodies against the S protein over the course of infection. 106 We also studied the IgG subclasses response against the S protein to understand the 107 involvement of different IgG subclasses in immunity against COVID-19. ACE2-huFc (ACE2 protein tagged with a human Fc) and S protein RBD-specific monoclonal 120 antibody clone 5A6 20 to the S protein-expressing cells ( Figure S1 ).

Using the SFB assay, we examined the antibody response against the full length S 122 protein in symptomatic COVID-19 patients (n=81 ; Table S1 ) over the course of infection, at 123 time points of median 5 days, 10 days and 23 days post-illness onset (pio). Various groups of 124 controls (Table S1 ) were also assessed in parallel: (1) recovered SARS individuals (n=20),

(2) healthy controls (n=22), and (3) seasonal human CoV patients (n=20). In the assay, the 126 plasma samples were screened for specific S protein antibodies by first incubating the 127 lentiviral-transduced cells with diluted plasma samples, and then followed by a secondary 128 incubation with fluorophore-conjugated anti-human antibody to detect antibody binding.

Specific IgM against the S protein was detected in COVID-19 patients, with the response 130 being higher at median 10 and 23 days pio than median 5 days pio ( Figure 1A) . A total of 131 32% of the patients had a positive IgM response as early as median 5 days pio ( Figure 1D ).

By median of 10 days pio, 63% of the patients acquired IgM, while 92% of the patients 133 acquired IgM at median of 23 days pio. Notably, specific IgM was not detected in all control 134 groups, highlighting the specificity of the assay ( Figure 1A and 1D). Similar to IgM, specific 135 J o u r n a l P r e -p r o o f IgA response was detected as early as median 5 days pio, with the highest response at median 136 23 days pio ( Figure 1B ). Specific IgA response was detected in 35% of the patients at 137 median 5 days pio, 66% of the patients at median 10days pio and 98% of the patients at 138 median 23 days pio ( Figure 1E ). The specific IgG response was also highest at median 23 139 days pio ( Figure 1C ). IgG seroconversion was detected in 47% pf the patients at median 5 140 days pio and 86% of the patients at median 10 days pio ( Figure 1F ). By median 23 days pio, 141 100% seroconversion was achieved. Four recovered SARS individuals also demonstrated IgG 142 cross-reactivity against the SARS-CoV-2 S protein ( Figure 1C and 1F). IgG1 is the dominant IgG subclass specific against S protein 146 We went on to study the specific S protein IgG subclasses profile of COVID-19 147 patients. All four IgG subclasses were detected in the patients, with responses being highest days pio and 23 days pio respectively) and IgA detection (35%, 66% and 98% at time point 171 of median 5 days pio, 10 days pio and 23 days pio respectively) was comparable. The SFB 172 assay was more sensitive for IgG detection, 47%, 86% and 100% at median 5 days, 10 days 173 pio and 23 days pio respectively (Table 1) . Unsurprisingly, at median 5 and 10 days pio 174 where antibody responses were lower, the sensitivity of the SFB assay for IgG1, IgG2, IgG3 175 and IgG4 detection was also lower. At a later time point of median 23 days pio, the SFB 176 assay was more sensitive for IgG1 and IgG3 detection (100% and 94% respectively), but less 177 sensitive for IgG2 and IgG4 detection (74% and 63% respectively). 

In comparison, we found the SFB assay to be highly sensitive. With PCR-positive and 218 symptomatic infections, the SFB assay was comparable to the two commercially available 219 assays, detecting 100% of the infections ( Figure 4G ). More importantly, the SFB assay was 220 able to detect 97% of PCR-positive and pre-/asymptomatic infections, as compared to 32% 221 and 35% with the cPass and RDT assays respectively. For PCR-positive and unknown 222 symptom status samples, the SFB assay detected 100% of samples, as compared to 18% with 223 the cPass assay. Similarly, for the rest of the three groups, the SFB assay was more sensitive 224 than the cPass and RDT assays ( Figure 4G ), being able to detect 62% of the PCR-negative 225 and unknown symptom status samples, 95% of the PCR-negative/not done and no symptom 226 infections, and 80% of the PCR-unknown and unknown symptom status samples. These 227 findings demonstrated the high sensitivity of the SFB assay, suggesting that the assay could 228 be an instrumental tool to detect asymptomatic infections. One defining feature of the assay is its ability to detect specific IgG subclasses against 246 the S protein. In our cohort, we found that all IgG subclasses were acquired by COVID-19 247 patients, with IgG1 being the most dominant. Similar to total IgG, the IgG subclasses With increasing reports of asymptomatic individuals having similar transmission 257 capability as symptomatic individuals 27, 28 , it is crucial to stem asymptomatic transmission as 258 well for effective COVID-19 disease control. We found that the SFB assay was able to detect 259 97% of the pre-/asymptomatic infections. The SFB assay could be a more effective tool for 260 detecting COVID-19 infections and might be more informative at determining exposure.

While the sensitivity for the cPass assay 29 and the RDT assay 30 was reported to be 94% and 262 86% respectively, we found that the SFB assay was more sensitive and was able to detect 263 specific antibodies in cases where discrepant or borderline results were achieved on the 264 commercial cPass and RDT assay. The antibody response was significantly lower in the 265 PCR-positive and pre-/asymptomatic patients than in symptomatic patients, which is in 266 agreement with a recent study 31 . Despite the lower antibody levels, the assay was able to 267 detect 97% of these infections, whereas the cPass and RDT did not yield clear serological 268 outcomes. This showed that more sensitive assays, such as the SFB assay, are needed to 269 detect pre-/asymptomatic infections, where the antibody response is weaker, and especially 270 for determining exposure in the population, The higher sensitivity of the SFB assay over the 271 cPass assay could be attributed to the target of the assay -the SFB assay is based on full 272 length S protein, which allows capture of antibodies against various domains and also 273 conformational epitopes, while the cPass assay was designed to detect specifically 274 neutralising antibodies against the RBD of the S protein that block the interaction between 275 the RBD domain and ACE2, its receptor on the host cell. The target of the RDT has not been 276 disclosed. It is possible that it is also based on a particular domain of the S protein, hence 277 capturing a smaller repertoire of S protein antibodies. It is also possible that the target is a 278 different protein such as the N protein, and thus recognising a different set of antibodies with 279 J o u r n a l P r e -p r o o f different kinetics in antibody induction. Of importance, IgG1 subclass detection by the SFB 280 assay was key to ascertain exposure to the virus and provide better sensitivity than testing 281 IgG alone -a significantly greater IgG1 response, as compared to total IgG, was observed in 282 all groups (Figure 4) . It is possible that the secondary anti-human IgG antibodies might not 283 bind to all IgG subclasses with similar efficiency. More importantly, the greater IgG1 284 response (over total IgG) could be due to a prozone effect, where high levels of antibodies 285 results in lack of antigen binding 32-35 . While there is likely a decrease in IgG levels over 286 time 36, 37 , it is also possible that the lack of IgG binding could be, in part, due to prozone 287 effect. We selected eight samples from the NPHL cohort, where the IgG1 response is greater 288 than the IgG response, and performed the SFB assay with serially-diluted samples. We 289 observed a higher IgG response at a higher dilution factor of 300, while the IgG1 response is 290 higher at a lower dilution factor of 100 ( Figure S2 )., suggesting that the greater IgG1 291 response (over IgG) could, in part, be due to a prozone effect. Hence, the detection of a 292 subset of total IgG, the IgG1 antibodies, might be better than the whole repertoire of total 293 IgG.

Serological assays are complementary to PCR assays for COVID-19 diagnosis. As a 295 preliminary evaluation of the SFB assay for ongoing sero-epidemiological studies, we tested 296 potentially exposed individuals who were PCR-negative from our NPHL cohort. The SFB 297 assay detected 8/13 (62%) of such samples, that were borderline positive or discrepant with 298 the cPass and RDT assays, indicating that a fraction of them have been infected/exposed to The SARS-Cov-2 S gene (GenBank: QHD43416.1), which encodes for the S protein, was 510 codon-optimised (Table S2) for expression by human mammalian cells. Full length S gene 511 was cloned into pHIV-eGFP transfer plasmid, via the XbaI and BamHI sites, upstream of an 512 IRES (internal ribosome entry site) and a eGFP gene (Table S2) 

WHO. WHO Coronavirus Disease

New SARS-like virus in China triggers alarm

A new coronavirus 596 associated with human respiratory disease in China

A pneumonia 598 outbreak associated with a new coronavirus of probable bat origin

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

Molecular Diagnosis of a Novel Coronavirus (2019-nCoV) Causing an Outbreak of Pneumonia

Persistent viral RNA shedding after COVID-605 19 symptom resolution in older convalescent plasma donors

SARS-CoV-2 Viral 609 Load in Upper Respiratory Specimens of Infected Patients

Serological Approaches for COVID-19: 611 Epidemiologic Perspective on Surveillance and Control

COVID-19) Update: FDA Expedites Review of Diagnostic Tests

19-update-fda-expedites-review-diagnostic-tests-combat-covid-615 19

Preliminary Identification of Potential 620

Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological 621 Studies. Viruses 12

Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses

An evaluation of COVID-19 serological assays informs future diagnostics and 627 exposure assessment

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven 630

Cross-reactive 632 antibody response between SARS-CoV-2 and SARS-CoV infections. bioRxiv

Characterization of the 634 receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD 635 protein as a viral attachment inhibitor and vaccine

A serological assay to detect SARS-CoV-2 seroconversion in humans. medRxiv

Bivalent 639 binding of a fully human IgG to the SARS-CoV-2 spike proteins reveals mechanisms of potent 640 neutralization. bioRxiv

Linear B-642 cell epitopes in the spike and nucleocapsid proteins as markers of SARS-CoV-2 exposure and disease 643 severity

Detection of SARS-645

CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals

Evaluation of 648 T helper-1/-2 balance on the basis of IgG subclasses and serum cytokines in children with 649 glomerulonephritis

IgG3 enhances neutralization potency and Fc effector function of an HIV V2-specific 652 broadly neutralizing antibody

Specific IgG3 and IgG1 Responses Are Associated with Clearance of Acute Hepatitis C Virus Infection. 655 Viruses 12

Human IgG subclasses: in vitro neutralization of and in vivo protection against West Nile 658 virus

Presumed Asymptomatic 660 Carrier Transmission of COVID-19

Clinical characteristics of 24 662 asymptomatic infections with COVID-19 screened among close contacts in Nanjing

Clinical and 669 immunological assessment of asymptomatic SARS-CoV-2 infections

Protective mechanism of the immune 671 response to a ribosomal vaccine from Pseudomonas aeruginosa. II. In vitro bactericidal and 672 opsonophagocytic studies with specific antiserum

Importance of complement source in bactericidal 674 activity of human antibody and murine monoclonal antibody to meningococcal group B 675 polysaccharide

More is not necessarily better: 677 prozone-like effects in passive immunization with IgG

Monoclonal 679 Antibodies of a Diverse Isotype Induced by an O-Antigen Glycoconjugate Vaccine Mediate In Vitro 680 and In Vivo Killing of African Invasive Nontyphoidal Salmonella

Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19

Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection. medRxiv

Clinical 688 assessment of COVID-19 outbreak among migrant workers residing in a large dormitory in Singapore

A 691 comparison of four serological assays for detecting anti-SARS-CoV-2 antibodies in human serum 692 samples from different populations

Investigation of three clusters of COVID-19 in Singapore: implications for surveillance and response 697 measures

SARS 699 in Singapore--predictors of disease severity

Detection of viral 701 respiratory pathogens in mild and severe acute respiratory infections in Singapore